所有图片(2)

文件

480894

O-(四氢-2H-吡喃-2-基)羟基胺

Name: <I>O</I>-(四氢-2<I>H</I>-吡喃-2-基)羟基胺
Brand: ALDRICH

96%

登录查看公司和协议定价

所有图片(2)

经验公式（希尔记法）:

C₅H₁₁NO₂

CAS号:

6723-30-4

分子量:

117.15

MDL编号:

MFCD01321374

PubChem化学物质编号:

24871725

NACRES:

NA.22

检测方案

96%

bp

81 °C/20 mmHg (lit.)

mp

34-37 °C (lit.)

SMILES string

NOC1CCCCO1

InChI

1S/C5H11NO2/c6-8-5-3-1-2-4-7-5/h5H,1-4,6H2

InChI key

NLXXVSKHVGDQAT-UHFFFAOYSA-N

一般描述

O-(四氢-2H-吡喃-2-基)羟基胺（OTX）是一种O-取代的羟胺。据报道，OTX与碱性凝胶电泳结合，可改善检测DNA中单链断裂（SSB）的过程。

应用

O-(四氢-2H-吡喃-2-基)羟基胺可用于合成2-(5-溴噻吩-2-磺酰胺基)-N-(四氢-2H-吡喃-2-基氧基)乙酰胺。
它可用于合成以下潜在的组蛋白脱乙酰酶（HDAC）抑制剂：

2-[1-(萘-2-磺酰基)-杂环基]-嘧啶-5-羧酸(四氢吡喃-2-基氧基)-酰胺
(E)-3-(2-苄基-1-氧代异吲哚-6-基)-N-(四氢-2H-吡喃-2-基氧基)丙烯酰胺
3-(1-苯磺酰基-2,3-二氢-1H-吲哚-5-基)-N-羟基丙烯酰胺

象形图

GHS07

警示用语：

Warning

危险声明

H315 - H319 - H335

预防措施声明

P261 - P264 - P271 - P280 - P302 + P352 - P305 + P351 + P338

危险分类

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

靶器官

Respiratory system

储存分类代码

11 - Combustible Solids

WGK

WGK 3

闪点(°F)

179.6 °F - closed cup

闪点(°C)

82 °C - closed cup

个人防护装备

dust mask type N95 (US), Eyeshields, Gloves

分析证书(COA)

输入产品批号来搜索分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

为方便起见，与您过往购买产品相关的文件已保存在文档库中。

访问文档库

难以找到您所需的产品或批次号码？

如何查找产品货号

在网站页面上，产品编号会附带包装尺寸/数量一起显示（例如：T1503-25G）。请确保在“产品编号”字段中仅输入产品编号 (示例: T1503).

示例

T1503

货号

25G

包装规格/数量

其它示例：

705578-5MG-PW

PL860-CGA/SHF-1EA

MMYOMAG-74K-13

1000309185

输入内容 1.000309185)

遇到问题？欢迎随时联系我们技术服务寻求帮助

如何查找COA批号

批号可以在产品标签上"批“ （Lot或Batch）字后面找到。

Aldrich 产品

如果您查询到的批号为 TO09019TO 等，请输入去除前两位字母的批号：09019TO。
如果您查询到的批号含有填充代码（例如05427ES-021），请输入去除填充代码-021的批号：05427ES。
如果您查询到的批号含有填充代码（例如 STBB0728K9），请输入去除填充代码K9的批号：STBB0728。

未找到您寻找的产品？

部分情况下，可能未在线提供COA。如果搜索不到COA，可在线索取。

索取COA

Design, synthesis, and evaluation of cyclic amide/imide-bearing hydroxamic acid derivatives as class-selective histone deacetylase (HDAC) inhibitors.

Chihiro Shinji et al.

Bioorganic & medicinal chemistry, 14(22), 7625-7651 (2006-08-01)

A series of hydroxamic acid derivatives bearing a cyclic amide/imide group as a linker and/or cap structure, prepared during our structural development studies based on thalidomide, showed class-selective potent histone deacetylase (HDAC)-inhibitory activity. Structure-activity relationship studies indicated that the steric

Synthesis and biological evaluation in U87MG glioma cells of (ethynylthiophene)sulfonamido-based hydroxamates as matrix metalloproteinase inhibitors.

Elisa Nuti et al.

European journal of medicinal chemistry, 46(7), 2617-2629 (2011-04-26)

Matrix metalloproteinases (MMPs) are important factors in gliomas since these enzymes facilitate invasion into the surrounding brain and participate in neovascularization. In particular, the gelatinases (MMP-2 and MMP-9), and more recently MMP-25, have been shown to be highly expressed in

Tetrahedron Letters, 45, 133-133 (2004)

Discovery of pyrimidyl-5-hydroxamic acids as new potent histone deacetylase inhibitors.

Patrick Angibaud et al.

European journal of medicinal chemistry, 40(6), 597-606 (2005-06-01)

A series of pyrimidyl-5-hydroxamic acids was prepared for evaluation as inhibitors of histone deacetylase (HDAC). Amino-2-pyrimidinyl can be used as a linker to provide HDAC inhibitors of good enzymatic potency.

Anticancer activity of MPT0E028, a novel potent histone deacetylase inhibitor, in human colorectal cancer HCT116 cells in vitro and in vivo.

Han-Li Huang et al.

PloS one, 7(8), e43645-e43645 (2012-08-29)

Recently, histone deacetylase (HDAC) inhibitors have emerged as a promising class of drugs for treatment of cancers, especially subcutaneous T-cell lymphoma. In this study, we demonstrated that MPT0E028, a novel N-hydroxyacrylamide-derived HDAC inhibitor, inhibited human colorectal cancer HCT116 cell growth

查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门

文件